3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 1/2
2
Phase 1
2
Phase NA
1
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
18
Neoplasm Metastasis
6
Urogenital Neoplasms
1
Unilateral Breast Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
HR+/HER2- Breast Cancer
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Breast Cancer Female
1
Advanced Breast Cancer
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
abemaciclib
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled